Roche’s Accu-Chek SugarView App Receives CE Mark Approval for Non-Insulin-Dependent Patients with Type 2 Diabetes or Pre-Diabetes

 Roche’s Accu-Chek SugarView App Receives CE Mark Approval for Non-Insulin-Dependent Patients with Type 2 Diabetes or Pre-Diabetes

Roche’s Accu-Chek SugarView App Receives CE Mark Approval for Non-Insulin-Dependent Patients with Type 2 Diabetes or Pre-Diabetes

Shots:

  • Roche has received a CE mark for its Accu-Chek SugarView app leading towards the launch of the app in EU and other countries across the globe requiring CE mark. The app is designed to help non-insulin-dependent people with T2D/ pre-diabetes live healthier lives in-between doctors’ visits
  • Roche will enable app initially accessible on certain smartphone model via the Google Play Store, thus enabling broader access to therapy relevant information for diabetic patients
  • Accu-Chek SugarView is an easy-to-use app which bypasses the need for a blood glucose meter as it determines the blood glucose range using the Accu-Chek Active test strip and two photos were taken off the strip with a smartphone camera and algorithm assigns the blood glucose result on the test strip ranging from low to very high

Click here to­ read full press release/ article | Ref: Roche | Image: Accu-check

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post